Chemoradiation therapy (CRT) has evolved as a definitive treatment for many patients with advanced-stage pharyngeal or laryngeal cancer. This treatment modality has resulted in good disease-specific survival rates and locoregional control, but it is associated with a unique set of short-term and long-term adverse events. Protocols using various combinations of chemotherapy and radiation therapy techniques have therefore been investigated with the goal of maximizing disease control while minimizing toxicity. Unfortunately, the accounting of toxicities in many studies has not been comprehensive.
1